Odyssey Therapeutics
- Market cap
- 828.53M
- P/E (TTM)i
- -5.16
- P/Bi
- 1.97
- EPSi
- -3.15
- Div yieldi
- 0.00%
- 52W posi
- 15%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 95.02% -0.06pp
- Institutions
- 63 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Top holders as of 2026-06-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 19 buys · 5 sells
| Name | Role | Stake |
|---|---|---|
| Gary Glick | Chief Executive Officer | 0.87% |
| Jeffrey Leiden | Independent Chairperson | 0.63% |
| Ian Smith | Independent Director | 0.51% |
| Jason Haas | Chief Financial Officer | 0.13% |
| Valerie Odegard | Independent Director | 0.13% |
| Natalie Dales | Chief of Research Operations & Portfolio Strategy | 0.08% |
| Shelley Chu | Independent Director | 0.02% |
| Anthony Opipari | -- | 0.02% |
| TPG Capital, L.P. | -- | -- |
| Jolie Siegel | General Counsel | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-10 | TPG Capital, L.P. | -- | Other Acquisition | +423,111 | -- |
| 2026-05-10 | TPG Capital, L.P. | -- | Other Disposition | -2,351 | $18.00 |
| 2026-05-10 | TPG Capital, L.P. | -- | Private Acquisition | +1,388,889 | $18.00 |
| 2026-05-10 | TPG Capital, L.P. | -- | Other Derivative Disposition | -423,111 | -- |
| 2026-05-10 | TPG Capital, L.P. | -- | Derivative Exercise and Retained | +1,880,497 | -- |
| 2026-05-10 | Jeffrey Leiden | Independent Chairperson | Derivative Exercise and Sale | -17 | $18.00 |
| 2026-05-10 | Jeffrey Leiden | Independent Chairperson | Derivative Exercise and Retained | +31,644 | -- |
| 2026-05-10 | Shelley Chu | Independent Director | Private Acquisition | +11,111 | $18.00 |
| 2026-05-10 | Gary Glick | Chief Executive Officer | Derivative Exercise and Retained | +27,386 | -- |
| 2026-05-10 | Anthony Opipari | -- | Derivative Exercise and Sale | -4 | $18.00 |
| 2026-05-10 | Anthony Opipari | -- | Derivative Exercise and Retained | +7,502 | -- |
| 2026-05-10 | SR One Capital Management, LP | -- | Private Acquisition | +555,555 | $18.00 |
| 2026-05-10 | SR One Capital Management, LP | -- | Derivative Exercise and Sale | -1,780 | $18.00 |
| 2026-05-10 | SR One Capital Management, LP | -- | Derivative Exercise and Retained | +3,239,328 | -- |
| 2026-05-10 | Dimension Management, L.P. | -- | Private Acquisition | +1,111,111 | $18.00 |
| 2026-05-10 | Dimension Management, L.P. | -- | Derivative Exercise and Retained | +1,709,543 | -- |
| 2026-05-07 | Jeffrey Leiden | Independent Chairperson | Private Acquisition | +5,000 | $20.00 |
| 2026-05-07 | Jason Haas | Chief Financial Officer | Open Market Acquisition | +1,000 | $20.00 |
| 2026-05-06 | TPG Capital, L.P. | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-05-06 | Jeffrey Leiden | Independent Chairperson | Other Derivative Acquisition | +626,220 | $18.00 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:58:49 · For reference only, not investment advice and not tailored to your situation.